Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2021-03-26 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENTIN RELATION TO THE PROVISION FOR IMPAIRMENT FOR ASSETS
Regulatory Filings Classification · 95% confidence The document is an announcement from Yanzhou Coal Mining Company Limited regarding the provision for impairment of assets, including bad debts, inventory depreciation, and long-term equity investment impairment. It references the approval of this provision by the Board and Supervisory Committee, and includes opinions from independent directors. The document is regulatory in nature, disclosing a specific financial adjustment and its impact on profit, but it does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is also not a certification or officer attestation. The document is longer than 5,000 characters and provides substantive detail on the impairment provision, but it is primarily an announcement of a specific financial event and related board approvals rather than a full report. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2021-03-26 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-03-26 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-03-26 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-03-26 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2020
Annual Report Classification · 95% confidence The document is an announcement of annual results for the year ended December 31, 2020, including audited consolidated financial results, business highlights, and detailed financial and operational information. It contains comprehensive financial data, analysis of revenue, expenses, and losses, as well as business development and pipeline progress. The presence of full financial statements and detailed management discussion indicates this is a full annual report rather than a brief earnings release or announcement. The document length (15,000 characters) and content depth confirm it is not a short announcement or a report publication notice. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2020
2021-03-25 English
INSIDE INFORMATION - BUSINESS UPDATES
Regulatory Filings Classification · 95% confidence The document is an announcement from CStone Pharmaceuticals regarding the approval of a drug (GAVRETO) by the National Medical Products Administration (NMPA) of China. It provides business updates and details about the drug, clinical study results, and company information. The document is labeled as an "announcement" and is issued pursuant to the Listing Rules and inside information provisions. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a transcript, audit report, or management report. The content focuses on business updates and regulatory approval news, which fits best under a general regulatory announcement category. The document length is 7649 characters, which is substantial but the content is clearly an announcement rather than a full report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-03-24 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.